215 related articles for article (PubMed ID: 37256791)
1. Dose-Dependent Production of Anti-PEG IgM after Intramuscular PEGylated-Hydrogenated Soy Phosphatidylcholine Liposomes, but Not Lipid Nanoparticle Formulations of DNA, Correlates with the Plasma Clearance of PEGylated Liposomal Doxorubicin in Rats.
Subasic CN; Butcher NJ; Minchin RF; Kaminskas LM
Mol Pharm; 2023 Jul; 20(7):3494-3504. PubMed ID: 37256791
[TBL] [Abstract][Full Text] [Related]
2. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
[TBL] [Abstract][Full Text] [Related]
3. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
[TBL] [Abstract][Full Text] [Related]
4. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
5. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients.
Miao G; He Y; Lai K; Zhao Y; He P; Tan G; Wang X
J Control Release; 2023 Nov; 363():12-26. PubMed ID: 37717659
[TBL] [Abstract][Full Text] [Related]
6. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine).
Bavli Y; Chen BM; Gross G; Hershko A; Turjeman K; Roffler S; Barenholz Y
J Control Release; 2023 Feb; 354():316-322. PubMed ID: 36549393
[TBL] [Abstract][Full Text] [Related]
7. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
8. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
[TBL] [Abstract][Full Text] [Related]
10. Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells.
Shimizu T; Mima Y; Hashimoto Y; Ukawa M; Ando H; Kiwada H; Ishida T
Immunobiology; 2015 Oct; 220(10):1151-60. PubMed ID: 26095176
[TBL] [Abstract][Full Text] [Related]
11. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
12. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
[TBL] [Abstract][Full Text] [Related]
13. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.
Ju Y; Lee WS; Pilkington EH; Kelly HG; Li S; Selva KJ; Wragg KM; Subbarao K; Nguyen THO; Rowntree LC; Allen LF; Bond K; Williamson DA; Truong NP; Plebanski M; Kedzierska K; Mahanty S; Chung AW; Caruso F; Wheatley AK; Juno JA; Kent SJ
ACS Nano; 2022 Aug; 16(8):11769-11780. PubMed ID: 35758934
[TBL] [Abstract][Full Text] [Related]
14. Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity.
Mima Y; Abu Lila AS; Shimizu T; Ukawa M; Ando H; Kurata Y; Ishida T
J Control Release; 2017 Mar; 250():20-26. PubMed ID: 28179196
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
16. Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon.
El Sayed MM; Takata H; Shimizu T; Kawaguchi Y; Abu Lila AS; Elsadek NE; Alaaeldin E; Ishima Y; Ando H; Kamal A; Sarhan HA; Ishida T
J Control Release; 2020 Jul; 323():102-109. PubMed ID: 32278827
[TBL] [Abstract][Full Text] [Related]
17. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
18. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
[TBL] [Abstract][Full Text] [Related]
19. Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration.
Guerrini G; Gioria S; Sauer AV; Lucchesi S; Montagnani F; Pastore G; Ciabattini A; Medaglini D; Calzolai L
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012103
[TBL] [Abstract][Full Text] [Related]
20. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists.
Stavnsbjerg C; Christensen E; Münter R; Henriksen JR; Fach M; Parhamifar L; Christensen C; Kjaer A; Hansen AE; Andresen TL
J Control Release; 2022 Feb; 342():337-344. PubMed ID: 34973307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
